Intended for healthcare professionals


Reports cite cardiovascular risks of COX 2 inhibitors and NSAIDs

BMJ 2006; 333 doi: (Published 14 September 2006) Cite this as: BMJ 2006;333:565
  1. Janice Hopkins Tanne
  1. New York

    Cyclo-oxygenase-2 (COX 2) inhibitors and some other non-steroidal anti-inflammatory drugs (NSAIDs) may present cardiovascular and renal risks, say two papers published online ahead of print publication in JAMA.

    Embedded Image

    Dr David Graham: The FDA's concerns should now be “focused on patient safety rather than corporate profitability”


    And an accompanying editorial by David Graham, a Food and Drug Administration employee and whistleblower, criticises studies of COX …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription